Joshua Pink

1.5k total citations
29 papers, 1.1k citations indexed

About

Joshua Pink is a scholar working on Epidemiology, Economics and Econometrics and Infectious Diseases. According to data from OpenAlex, Joshua Pink has authored 29 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Epidemiology, 8 papers in Economics and Econometrics and 6 papers in Infectious Diseases. Recurrent topics in Joshua Pink's work include Health Systems, Economic Evaluations, Quality of Life (7 papers), Tuberculosis Research and Epidemiology (4 papers) and Pneumonia and Respiratory Infections (3 papers). Joshua Pink is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (7 papers), Tuberculosis Research and Epidemiology (4 papers) and Pneumonia and Respiratory Infections (3 papers). Joshua Pink collaborates with scholars based in United Kingdom, Switzerland and India. Joshua Pink's co-authors include Dyfrig Hughes, Munir Pirmohamed, Steven Lane, Rachel Court, Stavros Petrou, Alexander Tsertsvadze, Marie-Paule Kiény, Peter Auguste, Damien Longson and John T. O’Brien and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and Spine.

In The Last Decade

Joshua Pink

29 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joshua Pink United Kingdom 17 265 241 164 164 163 29 1.1k
Stella Leung Canada 24 532 2.0× 378 1.6× 224 1.4× 143 0.9× 113 0.7× 49 2.5k
Bernardo Rangel Tura Brazil 19 256 1.0× 310 1.3× 241 1.5× 81 0.5× 416 2.6× 96 1.6k
Juan Víctor Ariel Franco Argentina 23 333 1.3× 200 0.8× 235 1.4× 82 0.5× 54 0.3× 138 1.6k
Neri Alejandro Álvarez‐Villalobos Mexico 14 203 0.8× 201 0.8× 41 0.3× 63 0.4× 159 1.0× 65 1.1k
Nicolas Jovenin France 20 271 1.0× 430 1.8× 20 0.1× 176 1.1× 204 1.3× 61 1.5k
Taro Kojima Japan 19 122 0.5× 255 1.1× 42 0.3× 47 0.3× 182 1.1× 88 1.8k
Chung‐Chien Huang Taiwan 17 162 0.6× 157 0.7× 86 0.5× 76 0.5× 61 0.4× 56 953
Laura Becker United States 20 112 0.4× 162 0.7× 85 0.5× 58 0.4× 36 0.2× 71 1.1k
Vikas Suri India 16 102 0.4× 113 0.5× 54 0.3× 367 2.2× 160 1.0× 69 1.1k
Judith L. Kinman United States 16 566 2.1× 375 1.6× 44 0.3× 210 1.3× 184 1.1× 31 2.0k

Countries citing papers authored by Joshua Pink

Since Specialization
Citations

This map shows the geographic impact of Joshua Pink's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joshua Pink with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joshua Pink more than expected).

Fields of papers citing papers by Joshua Pink

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joshua Pink. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joshua Pink. The network helps show where Joshua Pink may publish in the future.

Co-authorship network of co-authors of Joshua Pink

This figure shows the co-authorship network connecting the top 25 collaborators of Joshua Pink. A scholar is included among the top collaborators of Joshua Pink based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joshua Pink. Joshua Pink is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cook, Penny A., et al.. (2024). Associations between prenatal alcohol exposure and early education outcomes: a matched controls study using the born in Bradford dataset. Journal of Developmental Origins of Health and Disease. 15. e29–e29. 1 indexed citations
2.
Pink, Joshua, et al.. (2023). Cost-Effectiveness Analysis of Antimicrobial Prescribing in the Treatment of Clostridioides Difficile Infection in England. PharmacoEconomics - Open. 7(5). 739–750. 1 indexed citations
3.
Hopkinson, Nicholas S, Andrew Molyneux, Joshua Pink, & Marie C. Harrisingh. (2019). Chronic obstructive pulmonary disease: diagnosis and management: summary of updated NICE guidance. BMJ. 366. l4486–l4486. 62 indexed citations
4.
Datta, Samik, Joshua Pink, Graham F. Medley, et al.. (2019). Assessing the cost-effectiveness of HPV vaccination strategies for adolescent girls and boys in the UK. BMC Infectious Diseases. 19(1). 552–552. 48 indexed citations
5.
6.
Mistry, Hema, Martin Connock, Joshua Pink, et al.. (2017). Autologous chondrocyte implantation in the knee: systematic review and economic evaluation. Health Technology Assessment. 21(6). 1–294. 191 indexed citations
7.
Auguste, Peter, Alexander Tsertsvadze, Joshua Pink, et al.. (2017). Comparing interferon-gamma release assays with tuberculin skin test for identifying latent tuberculosis infection that progresses to active tuberculosis: systematic review and meta-analysis. BMC Infectious Diseases. 17(1). 200–200. 106 indexed citations
8.
Pink, Joshua, Stavros Petrou, Esther Williamson, Mark A. Williams, & Sarah E Lamb. (2016). Economic and Health-Related Quality of Life Outcomes of Whiplash Associated Disorders. Spine. 41(17). 1378–1386. 24 indexed citations
9.
Auguste, Peter, Alexander Tsertsvadze, Rachel Court, & Joshua Pink. (2016). A systematic review of economic models used to assess the cost-effectiveness of strategies for identifying latent tuberculosis in high-risk groups. Tuberculosis. 99. 81–91. 12 indexed citations
10.
Pink, Joshua, et al.. (2016). Cost Effectiveness of HPV Vaccination: A Systematic Review of Modelling Approaches. PharmacoEconomics. 34(9). 847–861. 12 indexed citations
11.
Shah, Hiral, Melina Dritsaki, Joshua Pink, & Stavros Petrou. (2016). Psychometric properties of Patient Reported Outcome Measures (PROMs) in patients diagnosed with Acute Respiratory Distress Syndrome (ARDS). Health and Quality of Life Outcomes. 14(1). 15–15. 16 indexed citations
12.
Mulhern, Brendan, Joshua Pink, Donna Rowen, et al.. (2016). Comparing Generic and Condition-Specific Preference-Based Measures in Epilepsy: EQ-5D-3L and NEWQOL-6D. Value in Health. 20(4). 687–693. 25 indexed citations
13.
Pink, Joshua, Stavros Petrou, Esther Williamson, Mark A. Williams, & Sarah E Lamb. (2014). Properties of patient-reported outcome measures in individuals following acute whiplash injury. Health and Quality of Life Outcomes. 12(1). 38–38. 17 indexed citations
14.
Pink, Joshua, Munir Pirmohamed, & Dyfrig Hughes. (2013). Comparative Effectiveness of Dabigatran, Rivaroxaban, Apixaban, and Warfarin in the Management of Patients With Nonvalvular Atrial Fibrillation. Clinical Pharmacology & Therapeutics. 94(2). 269–276. 21 indexed citations
15.
Pink, Joshua, Munir Pirmohamed, Steven Lane, & Dyfrig Hughes. (2013). Cost-Effectiveness of Pharmacogenetics-Guided Warfarin Therapy vs. Alternative Anticoagulation in Atrial Fibrillation. Clinical Pharmacology & Therapeutics. 95(2). 199–207. 54 indexed citations
16.
17.
Pink, Joshua, Steven Lane, & Dyfrig Hughes. (2012). Mechanism-Based Approach to the Economic Evaluation of Pharmaceuticals. PharmacoEconomics. 30(5). 413–429. 17 indexed citations
18.
Pink, Joshua, Steven Lane, Munir Pirmohamed, & Dyfrig Hughes. (2011). Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. BMJ. 343(oct31 1). d6333–d6333. 169 indexed citations
19.
Pink, Joshua & Marie-Paule Kiény. (2004). 4th Meeting on novel adjuvants currently in/close to human clinical testing. Vaccine. 22(17-18). 2097–2102. 44 indexed citations
20.
Engers, Howard, et al.. (2003). Third meeting on Novel Adjuvants Currently in or Close to Clinical Testing. Vaccine. 21(25-26). 3503–3524. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stella Leung Breakdown of academic impact, for papers by Bernardo Rangel Tura Breakdown of academic impact, for papers by Juan Víctor Ariel Franco Breakdown of academic impact, for papers by Neri Alejandro Álvarez‐Villalobos Breakdown of academic impact, for papers by Nicolas Jovenin Breakdown of academic impact, for papers by Taro Kojima Breakdown of academic impact, for papers by Chung‐Chien Huang Breakdown of academic impact, for papers by Laura Becker Breakdown of academic impact, for papers by Vikas Suri Breakdown of academic impact, for papers by Judith L. Kinman
Rankless by CCL
2026